# Bacterial Preparations & Drugs Sector

Canonical URL: https://biopharmsignal.com/sector/bacterial-preparations-drugs

Bacterial Preparations & Drugs includes companies using live bacteria, bacterial consortia, or bacteria-derived products as therapeutic agents. This category can include microbiome therapeutics, engineered bacterial medicines, and other biologically active bacterial approaches.

Companies currently grouped under Bacterial Preparations & Drugs: 5

## Recent Sector News

- 2026-07-14 11:02 EST — SPRO — [Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-d8d87fa7) — Source: Spero Therapeutics
- 2026-06-04 11:00 EST — ANTX — [AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease) — Source: AN2 Therapeutics
- 2026-05-21 11:00 EST — ANTX — [AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference) — Source: AN2 Therapeutics
- 2026-05-13 16:05 EST — SPRO — [Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update) — Source: Spero Therapeutics
- 2026-05-11 20:01 EST — ANTX — [AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2026-05-07 20:01 EST — ANTX — [AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum) — Source: AN2 Therapeutics
- 2026-05-05 16:05 EST — SPRO — [Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026) — Source: Spero Therapeutics
- 2026-03-31 11:00 EST — ANTX — [AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease) — Source: AN2 Therapeutics
- 2026-03-26 16:05 EST — SPRO — [Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2025-operating-results-and-provides-a-business-update) — Source: Spero Therapeutics
- 2026-03-18 16:05 EST — SPRO — [Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026](https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-26-2026) — Source: Spero Therapeutics
- 2026-03-17 20:00 EST — ANTX — [AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2026-03-09 11:00 EST — ANTX — [AN2 Therapeutics Announces $40 Million Private Placement Financing](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-40-million-private-placement-financing) — Source: AN2 Therapeutics
- 2026-03-03 21:00 EST — ANTX — [AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-plans-to-advance-oral-epetraborole-into-phase-2-study-for-polycythemia-vera-pv) — Source: AN2 Therapeutics
- 2026-02-17 12:00 EST — ANTX — [AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-fireside-chat-at-leerink-global-healthcare-conference) — Source: AN2 Therapeutics
- 2026-01-12 12:00 EST — ANTX — [AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-fda-clearance-to-proceed-with-90-patient-investigator-initiated-trial-iit-of-epetraborole-in-patients-with-m-abscessus-lung-disease) — Source: AN2 Therapeutics
- 2025-12-19 08:00 EST — SPRO — [Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis](https://biopharmsignal.com/news/SPRO/spero-announces-nda-resubmission-of-tebipenem-hbr-by-gsk-to-the-fda-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis) — Source: Spero Therapeutics
- 2025-11-28 08:00 EST — SPRO — [Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Spero Therapeutics
- 2025-11-13 16:05 EST — SPRO — [Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-third-quarter-2025-operating-results-and-provides-a-business-update) — Source: Spero Therapeutics
- 2025-11-12 21:01 EST — ANTX — [AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2025-11-10 12:00 EST — ANTX — [AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-research-collaboration-with-gsk-to-advance-boron-based-leurs-inhibitors-targeting-tuberculosis-tb) — Source: AN2 Therapeutics

## Companies

- [AXDX](https://biopharmsignal.com/company/AXDX) — Accelerate Diagnostics
- [ACXP](https://biopharmsignal.com/company/ACXP) — Acurx Pharmaceuticals
- [ANTX](https://biopharmsignal.com/company/ANTX) — AN2 Therapeutics
- [ARMP](https://biopharmsignal.com/company/ARMP) — Armata Pharmaceuticals
- [SPRO](https://biopharmsignal.com/company/SPRO) — Spero Therapeutics